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Abstract
Age-related macular degeneration (AMD) is a leading cause of legal blindness in the Western world. There are effective
treatments for the vascular complications of neo-vascular AMD, but no effective therapies are available for the dry/atrophic
form of the disease. A previously described transgenic CFH-gene deficient mouse model, (cfh2/2), shows hallmarks of early
AMD. The ocular phenotype has been further analysed to demonstrate amyloid beta (Ab) rich basement membrane
deposits associated with activated complement C3. Cfh2/2 mice were treated systemically in both prophylactic and
therapeutic regimes with an anti-Ab monoclonal antibody (mAb), 6F6, to determine the effect on the cfh2/2 retinal
phenotype. Prophylactic treatment with 6F6 demonstrated a dose dependent reduction in the accumulation of both Ab
and activated C3 deposition. A similar reduction in the retinal endpoints could be seen after therapeutic treatment. Serum
Ab levels after systemic administration of 6F6 show accumulation of Ab in the periphery suggestive of a peripheral sink
mechanism. In summary, anti-Ab mAb treatment can partially prevent or reverse ocular phenotypes of the cfh2/2 mouse.
The data support this therapeutic approach in humans potentially modulating two key elements in the pathogenesis of
AMD – Ab and activated, complement C3.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of
blindness in those over 55 years in the developed world. There are
two major clinical presentations of AMD. Atrophic (dry) AMD is
characterised by the degeneration of retinal pigment epithelial
(RPE) and the neural retina. Early stages of atrophic AMD are
associated with the formation of drusen, under the RPE.
Progression to an end stage disease, where the RPE degenerates
completely and forms sharply demarcated areas of central cell loss,
leading to regional loss of vision, is termed geographic atrophy. In
a minority of AMD patients the disease progresses with the
development of choroidal neovascularisation, (CNV), known as
wet AMD, where the development of weak, leaky blood vessels can
result in haemorrhage and complete blindness. There has been
progress in developing treatments limiting blood vessel develop-
ment and leakage with molecules which inhibit either vascular
endothelial growth factor, (VEGF), or the VEGF receptor
signalling pathway. However, there is neither treatment for the
atrophic form of AMD nor for the prevention of its progression to
wet AMD, [1].
There are no animal models which provide all the character-
istics of human AMD pathology but there are some interesting
findings and parallels shown in the ocular phenotypes of transgenic
mice. Transgenic mice inactivated for the murine apolipoprotein
E (apoE) gene, but expressing the human Apo E variant, apoE3
Leiden, [2], and especially apoE4, show, on a high fat diet, ocular
phenotypes ranging from basal laminar deposits under the RPE to
drusen deposition and CNV [3]. Association of the apoE protein to
the apoE receptor 2 has been shown to trigger the endocytosis of
amyloid precursor protein, (APP) in neuroblastoma cells, leading
to the production of amyloid beta (Ab), [4]. Additionally, mice
disrupted for the neprilysin gene, which encodes a peptidase that
degrades Ab, have increased deposition of Ab under the RPE and
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also show increased RPE cell degeneration and a similar histology
to that observed in human AMD. [5]. Mouse models of
Alzheimer’s disease, (AD), over-expressing human APP, leading
to brain and later retinal deposition of Ab, suggest a role for Ab in
both AD and AMD, [6–9].
There are similarities between the drusen formation in AMD
and in formation of plaques in AD. Drusen contain similar protein
components to the plaques found in AD. ApoE and Ab are found
both in atrophic, AMD drusen and AD plaques. The Ab found in
drusen is thought to be locally derived from the RPE cells, [10].
The involvement of ageing and a secondary inflammatory process
also appears to be common in both AMD and AD. In the AMD
inflammatory process, there is an associated rise in expression of
both Ab protein and acute-proteins such as C-reactive protein
(CRP). Both of these protein classes may induce both complement
activation and the activation of pro-inflammatory cytokines.
Activated complement components are also found in drusen and
a number of polymorphisms in genes involved in the alternative
complement pathway are associated with AMD development.
Many polymorphisms have been described especially in the key
regulator complement factor H, (CFH), but also in Factor B, C2
and C3. The implication of such polymorphisms is a dysfunction-
ally activated or regulated alternative complement pathway.
Activated complement components lead to the formation of a
final membrane attack complex which can lyse cells, releasing
cytokines such as VEGF. In AD, deposition of plaques containing
Ab protein and neurofibrillary tangles are known to activate
complement; thus linking disease mechanisms with AMD, [11–
13].
The aged and aging complement factor H, (cfh2/2), deficient
mouse has a pathological retinal phenotype that may mirror some
of the changes found in AMD, with elevated outer retinal deposits
and complement C3 accumulation [14]. Here we investigate the
effects of systemic administration of an anti-Ab monoclonal
antibody (mAb), in both prophylactic and therapeutic regimes, on
the accumulation of Ab and activated complement C3 in the
retina of the cfh2/2 mouse.
Materials and Methods
Ethics Statement
All animal studies were ethically reviewed and carried out in
accordance with Animals (Scientific Procedures) Act 1986 (UK),
the University College London ethics committee approval and the
GSK Policy on the Care, Welfare and Treatment of Laboratory
Animals under a UK Home Office project license (PPL 70/6571).
Generation of Monoclonal Antibody, (mAb), 6F6, to Ab
Mice were immunised, via the intra peritoneal route, with a
synthetic peptide from a region of the human Ab sequence: N-
CGGGNKGAIIGLMVGG (27–38) conjugated to purified pro-
tein derivative, (PPD). Once the mice had reached optimal
response titres, hybridomas were generated by obtaining the
spleens cells and fusing these with myeloma cells, derived from
X63/Ag8.653, [15], using PEG (polyethylene glycol) methodolo-
gy. The resultant mixed cell population was then plated out into
96 well plates.
Hybridoma samples were screened against multiple forms of Ab
peptides including the immunogen used for immunization using
Fluorometric Microvolume Assay Technology (FMAT). Further
secondary screening was performed to confirm hits by on and off
rate ranking of binding to N-terminal biotinylated Ab (1–40) by
Biacore and absence of binding to human APP expressed on HEK
cells, (Biotechnology Research Institute, National Research
Council, Canada). Epitope mapping by ELISA using a set of 31,
12-mer overlapping peptides (data not shown) which covered the
complete sequence of the Ab 1–42 peptide was carried out on
selected hits. Antibody was purified on a large scale directly from
the hybridoma. In depth examination of the binding kinetics with
purified recombinant antibody material resulted in selection of
IgG2a mAb 6F6. 6F6 showed low single digit nM affinity by
Biacore to both human and rodent Ab 1–40 and 1–42 (data not
shown).
Generation of mAb 5G5 and an IgG2A isotype-specific
Control
5G5 is a GSK mouse monoclonal antibody specific for the C-
terminus of Ab 1–42, (epitope 35–42) and was generated in a
similar manner to 6F6 by immunization of C57Bl/6 mice with
human Ab peptide 37–42 conjugated to KLH. In a similar
manner to the generation of 6F6 and 5G5, an IgG2A mouse
monoclonal antibody was generated against a peptide motive in
the Human Papilloma Virus-11, E1 gene and this was used as an
isotype-specific control in some experiments.
Animals and Experimental Design
Mice, cfh2/2 were backcrossed onto the C57BL/6 genetic
background for more than 10 generations, were fed ad libitum and
housed conventionally with a 12 hour day light/dark cycle. The
anti-Ab antibody 6F6 was given systemically to mice both
prophylactically, (0.06, 0.3 & 0.6 mg), and therapeutically, (0.06
& 0.6mg), via intraperitoneal (IP) route, on a weekly dosing
regimen. Time-points for respective treatment were determined
based on the onset and progression of pathologies in the model.
The prophylactic treatment was started at 3 months of age, before
any significant accumulation of Ab starts and the therapeutic
treatment was started at the age of 6 months. The prophylactic
treatment was continued for duration of 3 months and the
therapeutic treatment was also performed for duration of 3 months
with an intermediate time-point at 1 month.
Prophylactic Treatment
Five groups of three-month old cfh2/2 (62 weeks), each
containing five animals (n = 5) were used for the prophylactic
treatment. The groups are described in detail in Table 1. To
determine baseline levels for IHC analysis, five untreated, three-
month old cfh2/2 mice were culled and their eyes were removed
and processed for immunostaining.
Therapeutic Treatment
Four groups of six month old cfh2/2 mice (61 month), were
used in the therapeutic treatment. The groups are described in
detail in Table 2. A further group, (n = 4), was used as baseline and
they were culled at 6 months of age and their eyes were removed
and processed for immunohistochemistry. An additional group of
wild type, (wt), C57BL/6 mice, (n = 4), aged six months were
injected weekly with 6F6 at a 0.6 mg dose, to monitor for any
effects of 6F6 on wt mice and these were culled and analyzed after
one month (4 weeks) of treatment.
Analysis of cfh2/2 mice after Systemic Administration of
6F6
Cfh2/2 mice were treated at three months, (prophylaxis), and
at six months, (therapy), weekly for 12 weeks. Efficacy end points,
for both regimes were IHC analysis and quantification of retinal
deposition of Ab and activated complement C3, demonstration of
Anti BAM mAb in cfh2/2 Mouse
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e65518
elevated levels of free Ab (1–40 and 1–42) and total Ab (1–42), free
and mAb complexes in sera.
In vivo Imaging
A modified confocal Scanning Laser Ophthalmoscope, (cSLO),
(HRA2, Heidelberg, Germany) was used where the diameter of
the confocal aperture was reduced to 100 mm and the power at the
pupil of the 488 nm Argon laser increased to 1.4 mW to improve
signal-to-noise. Reflectance images were made at 488 nm and
820 nm illumination and autofluorescence (AF) images were
generated at 488 nm excitation and .500 nm emission. Tomo-
graphic image stacks were made of the retina, where the focal
plane was sequentially moved vitreal to sclera to distinguish hyper-
fluorescent points associated with the RPE from other fluorescing
structures. All image sequences were captured at 8.9 Hz, 55u field-
of-view, and were digitized as 8-bit, 153661536-pixel image files,
resulting in an optimal lateral image resolution of 1.2 mm/pixel.
Optimal axial resolution in the mouse eye was estimated to be 5–
8 mm. The principal limiting factor affecting image quality and
resolution was scattering due to clouding of cornea and/or lens
cataract. Hyperfluorescent foci with a diameter .20 mm present
within a 900 mm radius of the optic disk (OD) in in vivo confocal
fluorescence fundus images made at the level of the subretinal
space of both eyes in animals of each test group were quantified
(retinae in eyes where excessive scattering in ocular media reduced
resolution were excluded from analysis).
Immunohistochemistry, (IHC)
Animals were euthanized by exposure to CO2. Both eyes of
each animal were used. Eyes were removed and fixed in 4%
paraformaldehyde in phosphate buffered saline (PBS), pH 7.4 for
1 h. After washing in PBS the eyes were cryoprotected in 30%
sucrose in PBS, the lens removed and the eye cups frozen in OCT
(Tissue Tek) using dry ice/acetone freezing slurry. Cryostat
sections (10 mm) were thaw-mounted onto charged slides. IHC
was performed at room temperature. On some occasions, (see data
Figure 1), sections were pre-treated with Sudan Black in order to
reduce autofluorescence signal from the retinal pigment epithelial
cell/Bruch membrane interface. Retinal sections were blocked for
1 hr in 5% normal donkey serum in 0.1 M phosphate buffer saline
(PBS), pH 7.4 with 0.3% Triton X-100, and incubated overnight
with primary antibodies (see Table 3), diluted with 1% normal
donkey serum in 0.1 M PBS with 0.3% Triton X-100. Primary
antibody exposure was followed by washing, three times in 0.1 M
PBS, and then incubated with respective secondary antibodies (see
Table 4), diluted in 2% normal donkey serum in PBS with 0.3%
Triton X-100 and the sections were exposed for 1 hour at room
temperature. Negative controls consisted of both an unrelated
isotype matched antibody, (see Table 3), or omission of the
primary antibody. After the secondary antibody incubation, the
sections were washed several times and the nuclei were
subsequently stained with 0.5 ml 49,6-diamidino-2-phenylindole
(1 ml of DAPI stock solution, Sigma-Aldrich, to 5 ml of 0.1 M
PBS) for 1 min. Slides were then washed several times with 0.1 M
PBS followed by four washes in Tris buffered saline (pH 7.4) and
finally glass coverslips were mounted in VECTASHIELD (Vector
Laboratories). Sections were viewed using an Epi-fluorescence
bright-field microscope (Olympus BX50F4, Olympus, Japan),
where data was captured as 24 bit colour images at 384063072
pixel resolution using Nikon DXM1200 (Nikon,Tokyo, Japan)
digital camera.
Table 1. Prophylactic administration schedule for 6F6 in cfh2/2 mice.
Group Description Dose per animal (mg) Dose (mg/kg) Strain Number/group
1 Vehicle (PBS) – – cfh2/2 5
2 6F6 60 3 cfh2/2 5
3 6F6 300 15 cfh2/2 5
4 6F6 600 30 cfh2/2 5
5 Background levels of
experimental endpoints in
3 month old animals
– – cfh2/2 5
doi:10.1371/journal.pone.0065518.t001
Table 2. Therapeutic administration schedule for 6F6 in cfh2/2 mice.
Group Description Dose per animal (mg) Dose (mg/kg) Strain
Number/group per time-point
(weeks)
1 Vehicle (PBS) – – cfh2/2 4 (4 wks) 8 (12 wks)
2 6F6 60 3 cfh2/2 4 (4 wks) 8 (12 wks)
3 6F6 600 15 cfh2/2 4 (4 wks) 8 (12 wks)
4 Background levels of
experimental endpoints
in 3 month old animals
– 30 cfh2/2 4 (4 wks)
5 6F6 Background levels
pre-treated & treated wild-type
600 – C57Bl/6 4 (4 wks)
doi:10.1371/journal.pone.0065518.t002
Anti BAM mAb in cfh2/2 Mouse
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Grading System for IHC Analysis of the Retinae of cfh2/2
mice
All IHC grading was performed in a masked manner by two
experienced observers on four slides per eye, (both eyes per
animal), with a minimum of four sections per slide (prophylactic
regime), and five sections per slide, (therapeutic regime). For the
baseline three month prophylactic group, this was only scored by
one observer as at this stage little deposition of Ab and activated
Figure 1. Retinal imaging and immunohistochemical analysis of 12 month old cfh2/2mice. (A) Scanning laser ophthalmoscope image of
the retinae: Large clusters of hyperfluorescent foci (showing as autofluorescent point sources are observed. (B–D) Immunohistochemically labelled
sections of the fluorescent debris/deposits, the majority of which may be containined within macrophages, often occur simultaneously on either side
of the RPE. (B) acts as a negative control for Ab detection by IHC (background signal from an isotype specific control antibody). The signal for
fluorescent debris, (yellow), was dampened by use of Sudan Black in all cases. RPE-associated foci, show cross-reactivity, (green, highlighted with
white arrows), to activated complement C3, (C3b+, detected with clone 2/11, #HM1065, Hycult Biotech, Table 3), (C), and Ab, (4G8+), (D). A-
scalebar = 200 mm; B–D scalebar = 25 mm. Blue label is DAPI, (4’, 6-diamidino-2-phenylindole), a nuclear stain. CHO= choroid, RPE = retinal pigment
epithelial cells.
doi:10.1371/journal.pone.0065518.g001
Table 3. Primary antibodies used for IHC detection in cfh2/2 mouse retinae.
Primary antibody Source Catalogue number Dilution
Mouse monoclonal antibody, 4G8, to amyloid beta
(biotinylated)
Covance SIG-39220 (SIG-39240) 1:500 (1:300)
Rat monoclonal antibody to mouse C3b/iC3b/C3c
clone 2/11
Hycult Biotechnology HM 1065 1:50
Mouse IgG2a kappa [MOPC-173] isotype control
monoclonal Ab
Abcam ab18413 1:100
Rabbit polyclonal to complement C3 Abcam ab11887 1:10
Anti-factor H goat polyclonal Calbiochem, Merck Bioscience 341267 1:50
Rabbit anti-rat polyclonal Ab to total C3 Hycult Biotechnology HP8022 1:50
doi:10.1371/journal.pone.0065518.t003
Anti BAM mAb in cfh2/2 Mouse
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complement C3 was found. The observer-based grading method
was deemed more appropriate compared to morphological
quantification due to the delicacy of sections and complexity of
anatomy. An example of the grading system for the immunohis-
tochemistry of retinal slides for Ab, from the therapeutic regime is
shown in Figure S1.
Comparison of Systemic 6F6 Administration to an IgG2A
Isotype Control in cfh2/2 mice
In a separate study, Cfh2/2 mice were treated at four months
with a weekly dose of either 0.6 mg of 6F6 or an IgG2A isotype
control, again via the intraperitoneal (IP) route for 12 weeks.
Additionally, some animals in each group were dosed monthly
with curcumin at 7.5 mg/kg i.v. to provide an alternative means of
visualizing Ab in hyperfluorescent foci [16]. At the end of the 12
weeks, animals from each group were similarly culled and eyes
were processed for analysis by IHC. For this study, data for non-
curcumin and curcumin-treated animals was pooled. The exact
composition of all the groups in this study follows: For the 6F6
group n= 7 eyes, (n = 4 non curcumin treated, n= 3 curcumin
treated), whereas for the IgG2A isotype control n= 6 eyes, (n = 2
non curcumin treated, n= 4 curcumin treated).
This study was performed by a different group of investigators
to the remainder of the study and although the end-points were
similar, some different methodology was used. Culling and ocular
IHC was similarly performed. Retinal sections were blocked for
1 hr in 5% normal goat serum in 0.1 M phosphate buffer saline
(PBS), pH 7.4 with 0.3% Triton X-100, before overnight
incubation with primary antibodies. Although the same primary
antibody was used for the detection of Ab deposition as in the
remainder of the study, (4G8, Table 3), this was biotin-labelled
and detected with Alexa Fluor 488 streptavidin, and a different
primary antibody was used to detect total C3, (Hycult biotech,
cat# HP8022) a rabbit polyclonal anti-Rat C3 antibody which
gave low background for IHC staining, (data from this study is
described solely in the final part of the Results section and was the
only occasion that the antibody combination described above was
used in this work).
All IHC grading was similarly performed by two experienced
observers in a masked fashion on two slides (six sections per slide)
per animal/eye in each test group. A slight modification of the
previous grading system was used to score IHC of the retinal slides
and this is detailed in Methods S1.
Statistical Analysis of Retinal Data Points after Treatment
Regimes
The key endpoint data from the systemic administration of 6F6
and control administrations were subject to rigorous independent
statistical analysis, (raw data from academic study investigators
were evaluated by a GSK statistician, [PO]). For examination of
the prophylactic regime, an analysis of variance was used to
analyze data separately for IHC Ab deposition level and IHC
activated complement C3 levels. This model included a term for
group and the eye was regarded as the experimental unit. For
analysis of the IHC data: (i) where an analyst had scored an eye
more than once, the mean score for that eye for that analyst was
used, (ii) where more than one analyst had scored an eye, the mean
of the analyst scores was used. For the therapeutic regime a similar
analysis was done for all end-points but the additional terms for
group, week and the group*week, interaction were used in the
ANOVA model. Again a single eye was regarded as the
experimental unit. Predicted group means were plotted, with
95% confidence interval. For the therapeutic regime, this was
done for each week of endpoint analysis. Where analysis was
performed on log10 scale, these data were back transformed to
provide geometric means. Comparisons of group vs vehicle were
made. For untransformed data, these are presented as differences
from vehicle with 95% confidence interval and p values. For log
transformed data, these are presented as ratios to vehicle with 95%
confidence interval and p values. To assess the robustness of
conclusions, a bootstrap test was performed. This simulates re-
randomizations of eyes to new treatment groups 10,000 times,
repeats the statistical analysis for each simulation, and compares
the significance of the observed comparisons in this study against
the range of possible results across simulations. The results are
presented as bootstrap p value, as is the full statistical analysis of
the key in vivo data which are also shown in Table form in the
Supporting Information section. Data from the end-points of the
prophylactic regime: Ab IHC, (Table S1), activated complement
C3, (Table S2); and from the therapeutic regime: Ab IHC, (Table
S3), activated complement C3, (Table S4) can be viewed in detail
in the Supporting Information and the key significant findings are
summarised in the Results section of the main text.
The data from ‘the comparison of systemic administration of
6F6 to an IgG2A isotype control in cfh2/2 mice’, was similarly
analysed as raw data by the same statistician, with some minor
modifications in methodology. Where more than one analyst had
scored a histological slide, the mean of the analyst scores was used.
Where more than one histological slide had been scored for an
eye, the mean score over the slides was used. The bootstrap
analysis was not performed for the comparison of 6F6 v IgG2A
isotype control.
Immuno-assays and Statistics for PK and PD Analysis of
Amyloid Beta in Mouse sera/plasma
Two immunoassays were designed to assess the pharmocody-
namics of 6F6, (epitope 28–35), mediated transport of Ab from the
tissues to the periphery, [17], in cfh2/2 mice. This was achieved
by measuring free, (Ab 1–40 and 1–42), and total, (free and
antibody bound), Ab 1–42, in the serum/plasma samples taken
from treatment and control animals. This is summarized in
Table 4. Secondary antibodies used for IHC detection in
cfh2/2 mouse retinae.
Secondary
antibody Source
Catalogue
number Dilution
Alexa Fluor Donkey
anti Mouse 568
Invitrogen A10037 1:2000
Alexa Fluor Donkey
anti Rat 488
Invitrogen A21208 1:2000
Alexa Fluor Goat
anti Mouse 488
Invitrogen A21202 1:2000
Alexa Fluor Goat
anti Rat 594
Invitrogen A11007 1:2000
Alexa Fluor Goat
anti Rabbit 488
Invitrogen A21206 1:2000
Alexa Fluor Donkey
anti Goat 568
Invitrogen A10057 1:2000
Alexa Fluor Donkey
anti Rabbit 594
Invitrogen A21207 1:500
Alexa Fluor
Streptavidin 488
Invitrogen S11223 1:500
doi:10.1371/journal.pone.0065518.t004
Anti BAM mAb in cfh2/2 Mouse
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Table 5. To measure free Ab (non-drug bound) biotinylated 6F6
mAb, (4400 nM), was used as a capture reagent, and an Alexa
Fluor 647-labelled Ab-specific antibody, 4G8 (epitope 18–22),
Covance (Cat# SIG39220), 1000 nM, was used as detection
agent. To measure total Ab 1–42, biotinylated Ab-specific
antibody 5G5 (specific for Ab 1–42, C-terminal epitope 35–42),
was used for capture and the alexa-labelled Ab -specific antibody,
4G8 was used as detection. A 10 point standard curve was
generated using human Ab 1–42 peptide (Innogenetics NV, Cat
No: 80315) ranging from 20000 ng/ml to 31.25 ng/ml in human
Ab depleted plasma, (GSK ‘in house’ reagent). Both of the
described immunoassays were carried out on the Gyros AB
Gyrolab xP workstation using the Bioaffy 1000 CDs, (Gyros Cat
No: P0004253). All data generated for the Gyros immunoassays
were analysed using the Gyrolab evaluator.
For statistical analysis of the data, free Ab (1–40 and 1–42), and
total Ab 1–42 concentrations were log 10 transformed. Any values
below assay LLOQ were imputed as LLOQ/2. Group means 61
SD were calculated on the log scale and back transformed to
proved geometric means 61 SD range for bar plots. Analysis of
variance of log 10 transformed data was used to estimate and
compare geometric means with 95% confidence intervals. For the
therapeutic study, comparisons were made on individual time-
points, (week 0, 4 and 12 post-administration). Comparisons are
presented as ratios, with p values shown with/without multiple
comparison adjustment using false discovery rate (FDR), [18].
Results
Characterisation of cfh2/2 Mouse Model
The ocular phenotype of the the cfh2/2 mouse at two years of
age has been described [14], but the development of the ocular
changes at earlier time-points, (three months and twelve months)
has only be partially described, [19]. Further analysis of the cfh2/
2 mouse model was undertaken in this study to characterise the
earlier development of an ocular phenotype that could be used to
score an interventional study. Mice (n = 3), were also evaluated at
12 month old, (12MO) and an example of the retinal phenotypes
displayed by cfh2/2 mice is shown, in Figure 1. Large clusters of
hyperfluorescent foci were present (Figure 1A). These autofluor-
escent points were easily distinguished from other autofluorescent
structures as these patterns could also be seen in reflectance mode,
(data not shown). The points were subsequently discovered to
largely be present in the sub-retinal space, (Figure 1B–D). IHC
labelled sections from the same age group revealed an abundance
of partially digested fluorescent deposits, (yellow in the Figure),
adjacent to the RPE, which contained activated forms of C3,
(green-staining), labelled C3b+ (detected using clone 2/11,
HM1065, Hycult Biotech., see Table 3), (Figure 1C), and are
likely to be contained within macrophages, [20,21]. The basal side
of RPE showed extensive deposition of Ab, (labeled green in
Figure 1D), colocalising with the fluorescent debris (Figure 1D).
Sudan Black had been used in the experiments shown in Figure 1
to dampen autofluorescent signals so that it was clear that positive
IHC signals were genuine. A non-specific isotype control antibody
was used to generate the negative control data, (Figure 1B). Similar
hyperfluorescent spots have been seen in the retinae of C57Bl/6
mice though this is usually more pronounced at twenty four
months and they have been identified as macrophages or
microglia, [20]. Hyperfluorescent spots of macrophage origin
have been seen in other transgenic mouse knockout models where
the genotype accelerates the timing of their appearance with age,
[21].
Using IHC for detection, Ab+ staining appeared in retinae of 10
week-old cfh2/2 mice (n= 3), on the basal side of the RPE, (data
not shown). The appearance of Ab coincided with the time at
which complement C3, [19], and hyperfluorescent spots were first
detected by IHC and scanning laser ophthalmoscope (SLO),
respectively, (data not shown). Representative IHC from the
retinae of wild type, C57Bl/6, (wt) and cfh2/2 mice at 3 months,
(3MO), 6 months, (6MO) and 12 months, (12MO) are shown in
Figure 2. The data shows an increase in Ab deposition, shown as
4G8+ Ab cross-reactivity, (Figure 2), with time in both cfh2/2
and the age-matched control retinae. However, the rate of Ab
deposition in cfh2/2 mouse is substantially increased compared
to controls. The longitudinal analysis of Ab deposition in the retina
of the cfh2/2 mouse matches that for the deposition of
complement C3, [19]. IHC analysis has previously shown that
complement factor H expression is predominantly found along
Bruch’s membrane in the wild-type mouse, while in the cfh2/2
mouse model C3 deposition accumulates with age on Bruch’s
membrane [14]. Further analysis, had previously confirmed the
deposition of activated C3 fragments, (C3b, iC3b and C3c), see
also Figures 3 and 4, and presence along Bruch’s membrane in the
aged cfh2/2mouse, [19] and for clarity this matches the timing of
Ab deposition, (Figure 2). From the time-course studies of the
additional phenotyping of the cfh2/2 mice performed, it was
decided to nominally define the time-points for ‘prophylactic’
intervention in the model as three months, (just prior to the clear
detection of Ab and complement C3 deposition), and therapeutic
intervention at six months, the point at which these end-points
were clearly detectable, even in the absence of ocular functional
differences in the cfh2/2 mice at these times.
Prophylactic Treatment Regime
IHC analysis and quantification of Ab and activated
complement C3 levels at the base of the retinae. At
termination mice were culled, eyes were processed and IHC data
generated from the prophylactic treatment regime was graded as
described. Representative images are shown in Figure 3. Ab
deposition around the RPE/Bruch’s membrane, (red label), was
present in the control group at 6 months (Figure 3A) but was
clearly impacted by anti Ab mAb treatment in the prophylactic
regime (Figures 3B, 3C and 3D). The scoring of Ab load and
differences compared to the vehicle control group are shown in
Figure 3D and in Table S1. Ab was also, dependent upon fixation
Table 5. Summary of peripheral amyloid beta detection assays.
Purpose Capture antibody Detection antibody Comment
To detect free (not 6F6 bound) Ab
1–40 and Ab 1–42
6F6 epitope (28–35) 4G8 epitope (18–22) Ab epitopes can only confirm Ab 18–35
detection
To detect total (free and 6F6 bound)
Ab 1–42
5G5 epitope (35–42) 4G8 epitope (18–22) Ab epitopes can only confirm Ab 18–42
detection
doi:10.1371/journal.pone.0065518.t005
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Figure 2. Longitudinal study of Ab deposition along Bruch’s membrane in wt and cfh2/2 mice. Ab positive staining, (4G8+), is
highlighted in green along the boundary of the retinal pigment epithelial, cells and Bruch’s membrane, (highlighted with a green arrow head), at the
base of the retinae in the cfh2/2 mouse eye. Ab deposition increases with time in both cfh–/2, (B) 3 months, (D), 6 months and (F) 12 months, and
the age-matched control (wt), retinae, (A) 3 months, (C), 6 months and (E) 12 months. Ab deposition in cfh2/– mouse is elevated compared to wild
type (wt) at similar ages. Note that there are some autofluorescent deposits, (yellow), interspersed below the RPE with the 4G8+ staining in the aged
cfh2/2 samples: (D) & (F). Blue label is DAPI, (49,6-diamidino-2-phenylindole), a nuclear stain. Scalebar = 25 mm.
doi:10.1371/journal.pone.0065518.g002
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time, detected in some sections in outer segments and photore-
ceptors of cfh2/2 mice at three and six months of age, without
prophylactic treatment, (data not shown). Over-fixation can
sometimes lead to 4G8 cross-reactivity to the photoreceptor layer,
data not shown, but was not scored in this analysis and such
staining is not seen in Fig 2. Cross-reactive staining of the
photoreceptor layer with the 4G8 antibody is not a specific
phenotype of cfh2/2 mice but is also found in aged C57Bl/6
mice, but in both cases it is more pronounced at a later time of
age, about 12 months, [20], (data not shown). The data
demonstrated that: dosing with 6F6 significantly lowered the
amount of Ab deposited in the retinae of cfh2/2 mice by scores of
1.2 (p,0.0001), 0.9 (p,0.0001) and 0.4 (p = 0.0378), at the
600 mg, 300 mg and 60 mg doses, respectively.
Activated complement C3 levels in the RPE/Bruch’s mem-
brane were determined in a similar manner to that described for
Ab in IHC prepared retinal sections. Mean levels of activated
complement C3 deposition, (green label, detected using clone 2/
11, HM1065, Hycult Biotech., see Table 3), from 6F6 treated
animals, (Figures 3B, 3C and 3E), compared to vehicle treated
controls, (Figure 3A) are also shown in Figure 3. The scoring of
activated complement C3 and differences compared to the vehicle
control group are shown in Figure 3E and in Table S2. The data
demonstrated that in addition to lowering retinal Ab deposition:
dosing with 6F6 significantly lowered the amount of activated
complement C3 deposited in the retinae of cfh2/2 mice by a
score of 0.8 (p,0.0001), at a 600 mg dose, by a score of 0.75
(p,0.0001) at 300 mg dose, and by a score of 0.3 (p = 0.0938, non
significant trend, at 60 mg dose).
Therapeutic Treatment Regime
IHC analysis and quantification of Ab and activated
complement C3 levels at the base of the retinae. The
IHC staining was graded according to the level of deposition of Ab
(4G8+) and activated complement C3, (C3b+) as described for the
prophylactic regime. A representative image for both Ab and
activated complement C3 is shown in Figure 4. Ab (red) and
activated complement C3 deposition (green, detected using clone
2/11, HM1065, Hycult Biotech., see Table 3), around the RPE/
Bruch’s membrane was strongly evident in the negative control
group at nine months (Figure 4A) and was clearly impacted by 6F6
treatment in the therapeutic regime (Figures 4B, 4C and 4D). The
scoring of Ab load and differences compared to the vehicle control
group are shown in Figure 4D and in Table S3.
Dosing with 6F6 at 600 mg significantly lowered Ab deposited in
the retinae of cfh2/2 mice by a score of 1.25 (p = 0.0028) at week
4, and by 1.06 points at week 12 (p,0.0001). Dosing with 6F6 at
60 mg showed a significant lowering of the amount of Ab deposited
in the retinae of cfh2/2 mice by a score of 1 (p = 0.0069) at week
4 and significantly lowered score by 0.72 (p = 0.0008) at week 12.
Mean levels of Ab deposition in C57Bl/6 mice after 4wks
treatment with 6F6, (600 mg) showed a reduction over those in
cfh2/2 mice after the same treatment, (Figure 4D and Table S3),
which fits the lower rate of Ab deposition in wild type mice,
Figure 2, [20].
Activated complement C3 levels, (detected using clone 2/11,
HM1065, Hycult Biotech., see Table 3), in the RPE/Bruch’s
membrane were determined in a similar manner to that described
above for Ab. Activated complement C3 deposition differences
compared to vehicle treated controls are shown in Figure 4E and
in Table S4. The data demonstrated that: dosing with 6F6 at
600 mg significantly lowered the amount of activated complement
C3 deposited in the retinae of cfh2/2 mice by a score of 1.00
points at week 4 (p = 0.0379) and by 0.89 (p= 0.0002) at week 12;
dosing with 6F6 at 60 mg showed a non significant trend towards
lowering the amount of activated complement C3 deposited in the
retinae of cfh2/2 mice by a score of 0.75 (p = 0.0798) at week 4
and by a score of 0.34 (p = 0.1594) at week 12. Mean levels of
activated complement C3 deposition in C57Bl/6 mice after 4wks
treatment with 6F6, (600mg) showed a similar trend for reduction
to that seen in cfh2/2 mice after the same treatment, (Figure 4E
and Table S4).
Immuno-assays for PK and PD Analysis of Ab in Mouse
Sera
Quantification of unbound (free) Ab. Data showing these
analyses in summary are displayed in Figure S2 & Table S5
(Prophylactic regime) and Figures S3 & S4 & Table S6
(Therapeutic regime).
Cfh2/2 mice treated prophylactically with 6F6 showed a large
reduction in free, (non-antibody bound) Ab 1–40/1–42 compared
to controls, using the 6F6-4G8 Gyros assay. This is statistically
significant for all 6F6 dose groups but the 300 mg dosed group
showed more variability between individual serum samples and
the dose response is unclear.
Cfh2/2 mice treated therapeutically with 6F6 at 600 mg dose
showed a small reduction in free, (non-antibody bound), Ab 1–40/
1–42 levels in plasma, after 4 weeks treatment which was almost
statistically significant when compared to PBS controls, (see
Figures S3 & S4 & Table S6). Free Ab concentrations in the 6F6
treated animals were not substantially reduced compared to the
PBS controls at the 12 week time point.
Quantification of total Ab 1–42. The data in Figure 5 and
Figure S5 and Table S7 show the geometric mean total serum Ab
1–42 concentrations determined for treated cfh2/2 mouse groups
at the end of the prophylactic study. In 6F6 treated animals, at all
doses, there was a dramatic, statistically significant, (p,0.0001,
FDR adjusted), increase in total, (free and bound), Ab 1–42 when
compared to PBS-treated controls, which appears to reach
saturation at 300 mg dose and above, (Fig 5A & 5B).
The mean plasma total Ab 1–42 concentrations for all 6F6
dosed animals, (both cfh2/2 and C57Bl6), in the therapeutic
study, (see Figure 6 and Table S8), at the two time-points of 4
(Fig. 6B), and 12 weeks (Fig. 6C) show a dramatic statistically
significant, (p,0.0001, FDR adjusted), increase in total, (free and
bound), Ab 1–42 compared to PBS-treated controls. This increase
was dose-dependent although not dose-proportional. The mean
increase over baseline values observed for both the 60 mg and
600 mg 6F6 cfh2/2 treatment groups at 12 weeks, (Figs. 6A &
6C), was lower than the values seen at the 4 week time-point,
(Figs. 6A & 6B). This may indicate a long term depletion of Ab 1–
42, from the system at these high, weekly, systemic doses. Cfh2/2
mice have normal murine amyloid precursor protein, (APP)
expression and therefore have normal Ab 1–42, levels, unlike the
situation in transgenic mice which over-express human APP in the
brain, (so-called AD Tg mouse models), [22]. Consequently, the
increases seen in the wild type C57Bl/6 mice treated with 6F6 at
600 mg are comparable to those seen in the cfh2/2 mice after 4
weeks, (Fig. 6B).
Comparison of Systemic Administration of 6F6 to an
IgG2A Isotype Control in cfh2/2 mice
To address concerns that vehicle alone may not be an adequate
negative control for the previous experiments, a further study was
performed on 4 month-old cfh2/2 mice. The new study
compared the impact on the previously scored ocular measures
of animals treated with 600 mg 6F6 run ‘head to head’ with those
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treated with 600 mg of an IgG2A isotype control on a similar
weekly systemic administration regime.
From the analysis of both Ab and complement C3 deposition
around the RPE/Bruch’s membrane, the IHC score ranges for the
two subgroups +/2 curcumin overlapped, (see Figure S6) within
each treatment group so it was considered a reasonable approach
to pool the sub-groups for statistical analysis. The comparative
data for both Ab and complement C3 deposition is shown in
Figure 7, where it can be seen that treatment with 6F6 reduces
deposition of both Ab (p = 0.0232) and complement C3,
(p = 0.0414), with statistical significance, when compared to
treatment with an IgG2A isotype control. Note that in this study,
Figure 3. Immunohistochemical analysis of cfh2/2mice retinae after the prophylactic regime. Ab (4G8+, red) and activated complement
C3 (detected with clone 2/11+, #HM1065, Hycult Biotech., Table 3, green), cross reactivity to retinal sections at 6 months, (after 3 months dosing): (A)
negative control (PBS treated), 6F6, at 60 mg dose (B) and 600 mg dose (C), scalebar = 25 mm, PR=phototreceptors/outer segments, RPE= retinal
pigment epithelium, CHO= choroid, DAPI = 4’,6-diamidino-2-phenylindole. Left hand panel (A), (B), (C) is stained with DAPI, right hand panel (A), (B),
(C), is without DAPI staining. Ab deposition (D) and activated complement C3 deposition (E) in the RPE/Bruch’s membrane and/or along the outer
side of the choriocapillaris, (B), of cfh2/2 mice are plotted as differences from vehicle control with 95% confidence intervals (CI), after prophylactic
treatment in the test groups. Mice dosed with 6F6 show a dose dependent significant reduction, (asterisks, see text for levels of significance), in Ab
deposition at 60 mg, 300 mg and 600 mg and in activated C3 deposition at 300 mg and 600 mg compared to those treated with vehicle, (D) and (E)
respectively.
doi:10.1371/journal.pone.0065518.g003
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Figure 4. Immunohistochemical analysis of cfh2/2 mice retinae of after the therapeutic regime. Ab (4G8+, red) and activated
complement C3 (detected with clone 2/11+, #HM1065, Hycult Biotech., Table 3, green), cross reactivity to retinal sections at 9 months, (after 3
months dosing): (A) negative control (PBS treated), 6F6, at 60 mg dose (B) and 600 mg dose (C). Scalebar = 25 mm), PR =phototreceptors/outer
segments, RPE= retinal pigment epithelium, CHO= choroid, DAPI = 4’,6-diamidino-2-phenylindole. Left hand panel (A), (B), (C) is stained with DAPI,
right hand panel (A), (B), (C), is without DAPI staining. Ab (D), and activated complement C3, (E), deposition in the RPE/Bruch’s membrane of cfh2/2
mice, are plotted as differences from vehicle control with 95% confidence intervals (CI) after therapeutic treatment. Data in graphs (D) and (E) show
data at an intermediate time point, after 7 months of age (7MO), 1 month (+4w) after treatment as well as at the end of the regime at 9 months of age
(9MO), 3 months (+12w) after treatment. Data in graphs (D) and (E) also shows wild type (WT) mice treated with 6F6 (WT6F6) after 7 months of age
(7MO), 1 month (+4w) after treatment. Mice dosed with 6F6 show a dose dependent significant reduction, (asterisks, see text for levels of
significance), in Ab deposition at 60 mg and 600 mg and in activated C3 deposition at 600 mg compared compared to those treated with vehicle, (D)
at 9 months of age (9MO), 3 months (+12w) after treatment.
doi:10.1371/journal.pone.0065518.g004
Anti BAM mAb in cfh2/2 Mouse
PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e65518
total C3, (ie. both activated and uncleaved C3), was being detected
using a rabbit polyclonal anti-Rat C3 antibody, (Hycult biotech,
cat# HP8022, Table 3), and yet statistical significance for co-
clearance of Ab and complement C3 was still demonstrated by
IHC.
Discussion
Prophylactic treatment of cfh2/2 mice with 6F6 led to a dose
dependent, (3–30 mg/kg), reduction in the retinal deposition of
Ab and activated complement C3. Therapeutic treatment of cfh2/
2 mice with 6F6 at a 30mg/kg dose led to a significant reduction
in the retinal deposition of Ab and activated complement C3 after
both 4 and 12 weeks. Data obtained on retinal levels of Ab and
activated complement C3 were very carefully scored, mindful that
RPE/Bruch membrane derived autofluorescence did not impact
the interpretation of the results.
Levels of total Ab 1–42 peptide in the periphery of 6F6 treated
animals were dramatically increased compared to controls, after
both the prophylactic and therapeutic regimes, and this was dose
dependent. In animals treated therapeutically with 6F6 the
increase in mean peripheral Ab 1–42 levels was greater after 4
weeks than 12 weeks. This may be a result of depletion of systemic
Ab 1–42 peptide by the repeat dose antibody treatment. Taken
together, these data are in line with the concept that soluble Ab
available in the blood is effectively bound by 6F6 and that 6F6
may have Ab lowering effects on other compartments in the
animal, such as the eye, through the hypothesized peripheral sink
mechanism, increasing the total Ab in the blood stream [17,23].
Similar results have been obtained from plasma analysis from
systemically treating transgenic hAPP mice with 6F6 at compa-
rable doses, (unpublished data). A repeat experiment, initiated
three years after the original study by a different group of
investigators was performed in the cfh2/2 mice to compare the
effect of 6F6 treatment in parallel to treatment with a similar dose
of an IgG2A isotype control. The data generated from this study
verified the reduction in deposition of both Ab and complement
C3 after systemic treatment with 6F6 but not with an IgG2A
isotype control antibody and this was statistically significant in
both cases.
Recently published data suggest that Ab deposition occurs with
age even in the retina of wild type C57Bl/6 mice and that the
phenotype of the cfh2/2 mouse is super-imposed on an
accelerated version of what might occur at a later time-point in
Figure 5. Total Ab 1–42 levels in cfh2/2 mouse sera after prophylactic administration regime. Concentration of total Ab 1–42 in serum
samples treated systemically are shown as geometric means with standard deviation, (A) and with 95% Confidence Intervals from statistical analysis
(B). Data is shown at the end of the prophylactic regime, (6 months, after 3 months treatment), for n = 5 mice per treatment group, 6F6 dosed unless
stated. Note the substantial increases in serum total Ab 1–42 after 6F6 dosing, (see text for details). Statistical significance, p,0.0001, (FDR adjusted),
was reached for all doses of 6F6 over PBS controls, see Table S7.
doi:10.1371/journal.pone.0065518.g005
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wild type mice, [20]. In wild type mice similar hyperfluorescent
spots were described to those seen in cfh2/2 mice and it was
shown that these correspond to microglial cells that contain Ab,
[20]. Further aspects of the accelerated cfh2/2 ocular phenotype
may be related to exposure of the mouse model to external
pathogens, [24].
The eyes of aged, targeted-replacement apoE mice expressing
human Apo E4, (HuApoE4 KI), when placed on a high fat diet
developed changes which mimic AMD pathology with diffuse sub-
RPE deposits, Bruch’s membrane thickening, RPE atrophy, both
hypopigmentation and hyperpigmentation of the RPE [3]. In
some cases mice develop marked CNV and there is loss of retinal
function as measured by electroretinogram (ERG), [3]. The
HuApoE4 KI mouse model also demonstrates the presence of
murine Ab both associated with the CNV and with the outer
retinal deposits and the presence of elevated levels of murine
VEGF, [3]. The HuApoE4 KI mouse has been used to test the
hypothesis that the intraperitoneal injection of the Ab mAb, 2H6,
can be used to reduce the load of outer retinal deposits in a similar
way to the reduction of Ab containing plaques in the brains of AD
models. Preliminary evidence suggested that Ab basal deposits
were reduced in these mice upon systemic administration of anti-
Figure 6. Total Ab 1–42 levels in cfh2/2 mouse plasma after therapeutic administration regime. Concentration of total Ab 1–42 in
plasma samples treated systemically are shown as geometric means with standard deviation at baseline (A), (n = 12/group) and after 4 weeks (B),
(n = 4/group), and 12 weeks (C) of the therapeutic regime where final numbers were: PBS, vehicle n= 6; 6F6, 60 mg and 600 mg, n = 5. Labels are 6F6
dosed unless stated, Untrtd =untreated cfh2/2mice, WT600 mg=C57Bl/6 mice dosed with 6F6. Note the substantial increases in total plasma Ab 1–
42 after 6F6 dosing in cfh2/2 and C57Bl/6 mice at both the 4 (B) and 12 (C) week time-points, (see text for details). Statistical significance, p,0.0001,
(FDR adjusted), was reached for all doses of 6F6 over PBS controls, see Table S8.
doi:10.1371/journal.pone.0065518.g006
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Ab mAbs and that ERGs could be partially restored, [23, 25, 26,
27 & 28]. It is notable that in the HuApoE4 model 2H6 which also
only binds Ab 1–40 and not Ab 1–42 was only partially protective
[27,28]. A later study published by the same group, demonstrated
the ability of systemically administered anti-Ab mAbs to addition-
ally lead to a reduction in levels of activated complement C3 from
the retina of HuApoE4 mice, similar to here in cfh2/2 mice [28].
The most effective anti-Ab mAb in the second HuApoE4 study
was RN6G which has high affinity for both Ab 1–40 and Ab 1–42,
similar to 6F6. Note that 6F6 shows high affinity, single digit nM,
binding for both Ab 1–40 and Ab 1–42 and both a fast on rate and
a slow off rate for both peptides by SPR, (data not shown). The
accumulation of Ab in the periphery of mice with essentially
normal levels of rodent Ab, (rather than mice over-expressing
human Ab), is demonstrated here in cfh2/2 mice, after systemic
administration of anti-Ab mAbs and was also recently published
for the HuApoE4 model, [28]. The cfh2/2 mouse may represent
a rapid model to test the impact of therapies on clearance of
activated complement C3 and Ab deposition, however, cfh2/2
mice only have minor visual defects and these are more apparent
at two years of age, [14]. Attempts were made to analyse a small
sub group of negative control animals and high dose 6F6 treated
animals, from the therapeutic regime, for differences in retinal
function by ERG, (data not shown). There was no clear difference
between control and treated groups for the scotopic, a- & b-waves,
however data for the phototopic, a- & b- waves appeared to show a
a trend in favour of treated animals in this very small sample
group, (data not shown). It was deemed impractical to dose cfh2/
2 mice weekly from three to twenty-four months of age with high
doses of 6F6 to fully impact retinal function readouts in this model,
[14].
The link between the aetiology of AMD and AD has been
thoroughly reviewed recently [29]. While reducing amyloid
burden remains a key issue in both ageing and disease, it is
important to note that some forms of amyloid are critical for
normal biological function including synaptic plasticity and
memory [30,31]. Initial studies to characterize Ab in drusen,
appeared to highlight some differences from the Ab found in AD
plaques. The conclusions from these studies were that drusen
exhibit some of the characteristics of AD plaque Ab and contains
several Ab associated proteins but not Ab fibrils. However, one
study was unable to detect Ab peptide, nor amyloid precursor
protein, (APP) in drusen, [32]. This was in contrast to an early
study that had reported the reaction of drusen with monoclonal
antibodies directed against Ab peptide, [33]. Further very detailed
characterisation of drusen found Ab to associate with a sub-
structural vesicules co-localizing with activated complement
components C3, [34,35]. Ab could be an important component
of the local inflammatory events that lead to RPE atrophy, drusen
biogenesis and the pathogenesis of AMD. Ab-containing drusen
were also studied in 152 donor human eyes. Donors with AMD
possessed some drusen with the Ab assemblies. Vesicles were
sometimes found in the process of budding or fusing. Ab
immunoreactivity was also found in the cytoplasm of RPE cells
[35].The presence of Ab was confirmed in drusen and the
expression of APP, its progenitor, was highlighted in RPE cells
using a number of antibody reagents with documented binding
activity in AD plaques, [10].
Structures similar to the drusen associated ‘amyloid vesicles’
have been described in brains of transgenic mice expressing the
human APP protein [35]. A study to look at Ab in the drusen of
AMD compared to normal retinas found immunoreactivity in 4/9
AMD eyes and 0/9 normal eyes [36]). Further studies detected
oligomeric Ab in drusen which did not co-localize with ‘amyloid
vesicles’ [37]. Oligomeric Ab reactivity was seen in all drusen but
not in eyes without drusen. A recent study, [38], has shown a
variety of Ab stuctures in drusen vesicles including: non-fibrillar
oligomers, protofibrils and mature Ab of which non-fibrillar
oligomers appear to be the most abundant, [34]. Ab in drusen
could contribute to AMD by assembling into macromolecular
aggregates containing cytotoxic Ab peptide forms resulting in
direct killing of RPE and/or retinal ganglion cells [34]. Ab directly
interacts with VEGF and this may play a role in AD and AMD
pathogenesis [39]. Activation of the alternative complement
pathway triggers VEGF expression, but Ab can also induce
VEGF expression in human RPE cells in vitro [5].
A study of the prevalence of AMD amongst AD patients in the
USA found approximately double the number of expected cases,
[40]. Conversely a prospective population-based study identified
an increased risk of developing AD in individuals with advanced
AMD, [41]. However, a similar analysis of AMD levels performed
on participants in a cardiovascular health study concluded that
there was no significant association between AD and early AMD,
[42]. A recent study, [43], suggested an interaction between the
common AMD-associated CFH polymorphism Y402H, and the
APOE E4 allele together pre-disposing patients for co-morbidity in
AD and AMD. However, the Y402H polymorphism in the CFH
gene was not significantly associated with AD in two further
studies, [44 & 45].
Recently published data has shed light on the interaction of
complement proteins and Ab in the generation of AMD [46 & 47].
Ab has been shown to bind to complement factor I, (CFI), the co-
factor that with factor H is responsible for the breakdown of
complement protein C3 from the C3b form to its inactive form,
iC3b, [46]. These results support a hypothesis where Ab activates
the complement system within drusen by blocking the function of
CFI, leading to a low-grade, chronic inflammation in sub-retinal
tissues linking four of the factors associated with the development
Figure 7. Immunohistochemical analysis of cfh2/2mice retinae
after treatment with 6F6 v IgG2A isotype control Abs. Log
scored means +/2 SE for Amyloid b (4G8+, blue) and complement C3
(C3+, red, detected with rabbit anti-rat polyclonal Ab to total C3, Hycult,
HP80222, Table 3), deposition in retinal sections after 3 months of
dosing with: (i) 6F6, [solid bars]; (ii) IgG, IgG2A isotype specific negative
control Ab, [open bars], at 600 mg weekly doses. Group sizes,
n = numbers of eyes treated, are marked at the base of the bars in
parentheses. Differences of **p = 0.0232, for Amyloid b deposition and
of *p = 0.0414 for C3 deposition were noted comparing 6F6 treated
with IgG2A control. See SI Figure S6.
doi:10.1371/journal.pone.0065518.g007
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of AMD: inflammation, complement activation, Ab deposition
and drusen, [46]. Both Ab 1–40, [48], and Ab 1–42 [49], peptides
have been shown to induce inflammatory responses when
localizing to the rat retina after intravitreal injection, in the case
Ab 1–40 it has been shown to activate the NLRP-3 inflamma-
some, [48]. Ab has been shown both to increase the expression of
monocyte chemo-attractant protein-1, (MCP-1), in RPE cells and
to elevate the production of IL-1b and TNFa from macrophage
and microglial cells in vitro, [47]. The combined effect of co-
culturing macrophages and RPE cells with Ab is therefore to up-
regulate complement factor B, CFB, expression from RPE cells,
[47]. Ab could therefore have a combined mechanism of CFB
activation and CFI inhibition to activate the alternative comple-
ment pathway and accelerate the progression of AMD. Ab co-
localisation, interaction with and binding to iC3b and other
complement C3 components has been well-documented, [12,29].
One possible explanation for the co-clearance, after 6F6 admin-
istration, in the cfh2/2 mouse retina of Ab and activated
complement C3, is that complement is removed to the periphery,
bound to Ab. Note that Ab and activated complement C3
deposition in the retina of cfh2/2 mice have a very similar time
course of appearance.
In summary, this work provides further evidence that Ab may
be a key factor in AMD pathology and disease. The exact
mechanisms which cause the production of Ab from RPE and the
exact mechanism or mechanisms by which Ab acts to influence
AMD are not understood. However, current evidence implies that
clearing of Ab by agents that bind and potentially neutralise or just
remove Ab may provide a possible route to clearing drusen in
AMD, reducing complement activation, reducing RPE atrophy
and potentially reducing the induction of VEGF expression in
RPE and its localization at high levels around drusen. Such
therapy could therefore provide means of preventing, delaying,
attenuating or reversing the loss of vision due to AMD and its
progression to geographic atrophy and/or exudative AMD. This
may result in decreased levels of Ab and activated complement C3
containing drusen and/or local Ab in the surrounding environ-
ment of the RPE and thereby interfere in both the early and later
stages of AMD and treat the underlying cellular decline that causes
the loss of vision.
Supporting Information
Figure S1 Representative grading of the retinae of cfh2/2 mice
in the therapeutic regime scored for the level of Ab deposition by
immunohistochemistry (IHC). Ab staining is in red (4G8+) and is
indicated by white arrows. Blue label is DAPI, (49,6-diamidino-2-
phenylindole) a nuclear stain. Scalebars = 25 mm. ONL=Outer
nuclear layer, PR=photoreceptors, RPE/BR= retinal pigment
epithelium/Bruch’s membrane, CHO=choroid. Grading proto-
col for IHC: Grade 0, No deposition along the Bruch’s
Membrane, (A), Grade 1, Fragmented deposition or ,10%
deposition along Bruch’s membrane, (B), Grade 2, Segmental
deposition along 10–50% of Bruch’s membrane, (C), Grade 3,
Close to continuous deposition, or 50–75%, along the length of
Bruch’s membrane, (D), Grade 4, A continuous expression, or .7
5% of Bruch’s membrane, (data not shown).
(TIF)
Figure S2 Free Ab (1–40 & 1–42) levels in cfh2/2 mouse sera
after prophylactic administration regime. Concentration of free
Ab (1–40 &1–42) in serum samples are shown as geometric means
with standard deviation, (A) and with 95% Confidence Intervals
(B) Data are shown at the end of the prophylactic regime, (6
months, after 3 months treatment), for n= 5 mice per treatment
group, 6F6 dosed unless stated. Note the substantial decreases in
serum free Ab (1–40 & 1–42) after 6F6 dosing, (see text for details).
Statistically significant, (FDR adjusted), differences were reached
for 6F6 dosed animals over the PBS-dosed controls of p = 0.0003,
(60 mg), p = 0.0175, (300 mg) p =,0.0001, (600 mg), see Table S5.
(TIF)
Figure S3 Free Ab (1–40 & 1–42) levels in cfh2/2 mouse
plasma after therapeutic administration regime. Concentration of
free Ab (1–40 &1–42) in plasma samples are shown as geometric
means with standard deviation at baseline (A), (n = 12/group) and
after 4 weeks (B), (n = 4/group), and 12 weeks (C) of the
therapeutic regime where final numbers were: PBS, vehicle
n = 6; 6F6, 60 mg and 600 mg, n= 5. Labels are 6F6 dosed unless
stated, Untrtd = untreated cfh2/2 mice, WT600 mg =C57Bl/6
mice dosed with 6F6. Note a drop in plasma free Ab (1–40 & 1–
42) levels at a 600 mg dose of 6F6 at the 4 week time-point, which
is close to statistical significance, over PBS controls p = 0.1416,
(FDR adjusted), p = 0.0354 (non-adjusted), see Table S6.
(TIF)
Figure S4 Geometric mean free Ab (1–40 & 1–42) levels with
95% Confidence Intervals in cfh2/2 mouse plasma after
therapeutic administration regime.
(TIF)
Figure S5 Geometric mean total Ab 1–42 levels with 95%
Confidence Intervals in cfh2/2 mouse plasma after therapeutic
administration regime.
(TIF)
Figure S6 Comparison of relative spread of immunohistochem-
ical scoring of the retinae of cfh2/2 mice after treatment with 6F6
v IgG2A isotype control Ab. Data for geometric mean values of
IHC scores for Amyloid b (4G8= analyte): (A) scatter, (B) box &
tail, and complement C3, detected with rabbit anti-rat polyclonal
Ab to total C3, Hycult, HP80222, Table 3, (C3= analyte): (C)
scatter, (D) box & tail; were compared across the groups treated
with either 6F6 or IgG2A and further sub-divided into sub-groups
scored by standard autofluorescence, (AF, not further treated) and
those additionally dosed with Curcumin, (CU). For the scatter
plots: (A) & (C), a small constant greater than one was added to the
data to highlight any overlapping points that might mask the true
analysis of variability. For the 6F6 treated n= 7 eyes, (n = 4 AF,
non curcumin treated, n= 3 curcumin treated) and for the IgG2A
isotype control n = 6 eyes, (n = 2 AF, non curcumin treated, n = 4
curcumin treated). The IHC score ranges for the two subgroups
+/2 curcumin overlapped within each treatment group so it was
considered a reasonable approach to pool the sub-groups for
statistical analysis.
(TIF)
Table S1 Mean levels (A) and ratios to vehicle control group (B)
of Ab deposition in the RPE/Bruch’s membrane after prophylac-
tic treatment.
(TIF)
Table S2 Mean levels of activated complement C3 deposition
(A) and ratios to vehicle controls (B) in the RPE/Bruch’s
membrane after prophylactic treatment.
(TIF)
Table S3 Mean levels (A) and ratios to vehicle control group (B)
of Ab deposition in the RPE/Bruch’s membrane after therapeutic
treatment.
(TIF)
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Table S4 Mean levels (A) and ratios to vehicle control group (B)
of activated complement C3 deposition in the RPE/ Bruch’s
membrane after therapeutic treatment.
(TIF)
Table S5 Geometric means of free Ab 1–40/1–42 levels for
cfh2/2 mice at the end of the prophylactic regime in sera (A) and
statistical analysis (B).
(TIF)
Table S6 Geometric means of free Ab 1–40/1–42 levels for
cfh2/2 mice at the end of the therapeutic regime in plasma (A)
and statistical analysis (B).
(TIF)
Table S7 Geometric means of total Ab 1–42 levels for cfh2/2
mice at the end of the prophylactic regime in sera (A) and
statistical analysis (B).
(TIF)
Table S8 Geometric means of total Ab1–42 levels for cfh2/2
mice at the end of the therapeutic regime in plasma (A) and
statistical analysis (B).
(TIF)
Methods S1 Comparison of systemic administration of 6F6 to
an IgG2A isotype control in cfh2/2 mice using Curcumin as an
imaging marker.
(DOCX)
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